Association between ischaemic heart disease and interstitial lung disease: A case-control study

Respiratory Medicine

Volumn 103, Issue 4, 2009, Pages 503-507

  Ponnuswamy, A ^a   Manikandan, R ^a   Sabetpour, A ^a   Keeping, I M ^a   Finnerty, J P ^a  

^a Countess of Chester Hospital ^*  (United Kingdom)

Author keywords

Coronary artery disease; Interstitial lung disease; Pulmonary fibrosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FIBROSING ALVEOLITIS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; INTERSTITIAL LUNG DISEASE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; CASE CONTROL STUDY; COMORBIDITY; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; MYOCARDIAL ISCHEMIA; UNITED KINGDOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 60649088422     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.01.004     Document Type: Article

References (21)

1. Gribbin J., Hubbard R.B., Le Jeune I., Smith C.J.P., West J., and Tata L.J. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61 (2006) 980-985
2. Erwteman T.M., Braat M.C.P., and Van Aken W.G. Interstitial pulmonary fibrosis: a new side effect of practolol. Br Med J (1977) 297-298
3. Kiuru A., Yue, and Meyboom R.H. Pulmonary fibrosis reported with statins. Drug Safety 29 10 (2006) 911-1010
4. Weinstein A. Drug-induced systemic lupus erythematosus. Prog Clin Immunol 4 (1980) 1-21
5. Ahmad S. Lovastatin-induced lupus erythematosus. Arch Intern Med 151 (1991) 1667-1668
6. Zuech P., Pauwels C., Duthoit C., Méry L., Somogyi A., Louboutin A., et al. Pravastatin-induced dermatomyositis. Rev Med Interne 26 11 (2005 Nov) 897-902
7. Takagi A., and Shiio Y. Pravastatin-associated polymyositis, a case report. Rinsho Shinkeigaku 44 1 (2004 Jan) 25-27
8. Liebhaber M.I., Wright R.S., Gelberg H.J., Dyer Z., and Kupperman J.L. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 115 (1999) 886-889
9. Lantuejoul S., Brambilla E., Brambilla C., and Devouassoux G. Statin-induced fibrotic non-specific interstitial pneumonia. Eur Respir J 19 (2002) 577-580
10. Martin J., Denver R., Bailey M., and Krum H. Dose-dependent anti-fibrotic effects of statins in human cardiac fibroblast culture: an explanation for the non-pleiotropic effects of statins. Clin Exp Pharmacol Physiol (2005) 697-701
11. Vieira Jr. J.M., Rodrigues L.T., Mantovani E., Dellê H., Mattar A.L., Malheiros D.M., et al. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron Physiol 101 4 (2005) 82-91
12. Nadrous H.F., Ryu J.H., Douglas W.W., Decker P.A., and Olson E.J. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 126 (2004) 438-446
13. Baumgartner K.B., Samet J.M., Stidley C.A., Colby T.V., and Waldron J.A. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155 1 (1997) 242-248
14. Enomoto T., Usuki J., Azuma A., Nakagawa T., and Kudoh S. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 123 (2003) 2007-2011
15. Specks U., Martin W.J., and Rohrbach M.S. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am Rev Respir Dis 141 (1990) 117-123
16. Marshall R.P., McAnulty R.J., and Laurent G.J. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 161 (2000) 1999-2004
17. Tsuzuki S., Matoba T., Eguchi S., and Inagami T. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 93 (1996) 156-160
18. Konigshoff M., Wilhelm A., Jahn A., Sedding D., Amaria O.V., Eul B., et al. The angiotensin II receptor 2 is expressed and mediates angiotensin II signalling in lung fibrosis. Am J Respir Cell Mol Biol 37 (2007) 640-650
19. Rizer J.F., Zisman D.A., Blumenthal N.P., Kotloff R.M., et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med 164 (2004) 551-556
20. Apostopoulos J., Davenport P., and Tipping P.G. Interleukin-8 production by macrophages from atheromatous plaques. Arterioscler Thromb Vasc Biol 16 (1996) 1007-1012
21. Keane M.P., Arenberg D.A., Lynch J.P., Whyte R.I., et al. The CXR chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 3 (1997) 1437-1443